Vasodilators, such as calcium antagonists, phosphodiesterase type 5 (PDE5) inhibitors, and synthetic analogues of prostacyclin and endothelin receptor antagonists (ERAs), are indicated for the treatment of Raynaud phenomenon, ischemic digital ulcers, and PAH. Here, PDE5A is linked to pulmonary arterial hypertension.